ReNeuron Group Plc (LON:RENE)‘s stock had its “buy” rating reissued by equities researchers at Stifel Nicolaus in a research report issued on Thursday. They presently have a GBX 13 ($0.17) price target on the stock.
Separately, N+1 Singer restated a “corporate” rating on shares of ReNeuron Group Plc in a research note on Monday, October 9th.
ReNeuron Group Plc (LON:RENE) traded down GBX 0.05 ($0.00) during trading hours on Thursday, reaching GBX 2.10 ($0.03). The company’s stock had a trading volume of 2,000,000 shares, compared to its average volume of 1,880,000. ReNeuron Group Plc has a 12-month low of GBX 1.58 ($0.02) and a 12-month high of GBX 3.67 ($0.05).
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/11/stifel-nicolaus-reiterates-buy-rating-for-reneuron-group-plc-rene.html.
About ReNeuron Group Plc
ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP).
Receive News & Ratings for ReNeuron Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.